TIDMSLN

RNS Number : 7370D

Silence Therapeutics PLC

11 October 2018

US Patent Trial & Appeal Board (PTAB) Upholds Silence Patent by Denying First of Five Patent Grant Review Applications Filed by Alnylam

October 11 2018

LONDON, Silence Therapeutics plc, (LON:SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today reports on the favourable outcome of a decision by the US PTAB against Alnylam.

In the US, Alnylam filed a total of five Post Grant Review (PGR) petitions against newly-issued Silence patents challenging the validity of the issued claims. In the first decision on Alnylam's petitions, the PTAB denied institution of post-grant review, finding that Alnylam had not met its initial burden of showing that the claims are invalid.

The PTAB's decision not to institute review provides yet another vindication of the strength of Silence's worldwide patent portfolio.

Decisions on the remaining petitions are expected over the next several months.

David Horn Solomon, Chief Executive Officer of Silence Therapeutics, commented:

"We are very pleased with this favourable outcome in US patent office proceedings initiated by Alnylam. We are hopeful that the remaining proceedings will result in similar outcomes and that Silence's patent position will be fully vindicated."

Enquiries:

 
 Silence Therapeutics plc                       Tel: +44 (0)20 3457 
  Dr David Horn Solomon, Chief Executive         6900 
  Officer 
  David Ellam, Chief Financial Officer 
 
 Peel Hunt LLP (Nominated Adviser and Broker)   Tel: +44 (0)20 7418 
  James Steel/Oliver Jackson                     8900 
 European IR                                    Tel: +44 (0) 20 
  Consilium Strategic Communications             3709 5700 
  Mary-Jane Elliott / Angela Gray 
  silencetherapeutics@consilium-comms.com 
 US IR                                           Tel: +1 (212) 213-0006 
  Burns McClellan 
  Lisa Burns, Jill Steier, John Grimaldi 
  Silence.therapeutics@burnsmc.com

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCMMMMGLMZGRZG

(END) Dow Jones Newswires

October 11, 2018 05:14 ET (09:14 GMT)

Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2024 to May 2024 Click Here for more Silence Therapeutics Charts.
Silence Therapeutics (LSE:SLN)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Silence Therapeutics Charts.